Beyond Ruxolitinib as the Frontline Standard of Care: Current and Emerging Second-Line Therapies
 | Beyond Ruxolitinib as the Frontline Standard of Care: Current and Emerging Second-Line Therapies CME, NCPD, CPE Prithviraj Bose, MD; and Andrew Kuykendall, MD | |
| Release Date: December 14, 2022 Expiration Date: December 14, 2023 | ||
After defining and identifying treatment resistance and loss of response, it is time to look at second-line therapies. In this presentation, Dr. Bose and Dr. Kuykendall discuss available and emerging treatment strategies that may be implemented when patients fail to respond or lose response to ruxolitinib therapy. Additionally, these experts share recommendations and strategies for effectively transitioning from first- to second-line therapy. Provided by The University of Texas MD Anderson Cancer Center and MediCom Worldwide, Inc.This activity is supported by educational grants from Bristol Myers Squibb, CTI BioPharma Corp. and Sierra Oncology. | ||
| Begin, Earn CreditView Only, No Credit | ||